Pharmaceuticals

Rising Prevalence Of Blood Diseases Fueling The Growth Of The Due To Increasing Demand For Accurate Blood Typing And Transfusion Management Is Supporting Expansion In The Preventive Vaccines Market

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Preventive Vaccines Market Expected To Scale Between 2026 And 2030?

The preventive vaccines market size has demonstrated strong growth in recent years. This market is set to expand from $83 billion in 2025 to $90.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.8%. Factors contributing to its historical growth include the successful eradication and control of infectious diseases, government-led vaccination campaigns, increasing public health awareness, the establishment of global immunization programs, and augmented funding from international health organizations.

The preventive vaccines market is anticipated to experience robust expansion over the coming years. By 2030, its value is projected to reach $131.27 billion, exhibiting a compound annual growth rate (CAGR) of 9.8%. This expansion during the forecast period is fueled by factors such as the advancement of next-generation vaccine technologies, the increasing global population and urban development, heightened initiatives for outbreak preparedness, the broadening of adult immunization schemes, and the proliferation of public-private collaborations in vaccine creation. Key developments expected during this period involve the broadening of national immunization strategies, a heightened emphasis on proactive healthcare and disease management, a growing need for vaccinations for both children and the elderly, an increase in the adoption of combination and multivalent vaccines, and improvements in cold chain and vaccine storage infrastructure.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24667&type=smp

Which Key Factors Are Driving The Preventive Vaccines Market Growth?

The growing incidence of infectious diseases is poised to fuel the expansion of the preventive vaccines market. These diseases originate from pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, capable of transmission between individuals or through the surroundings. The increasing prevalence of these infections is exacerbated by factors including heightened urbanization, international travel, and antimicrobial resistance, which collectively enable quicker dissemination and more challenging containment. Preventive vaccines work by stimulating the immune system to recognize and fight off pathogens before an infection takes hold, thereby diminishing disease occurrence and transmission. For example, in 2024, the World Health Organization reported that new global cases of TB (tuberculosis) reached 8.2 million in 2023, marking an increase from 7.5 million in 2022. Consequently, the rising occurrence of infectious diseases is a key driver for the growth of the preventive vaccines market.

Which Segment Classifications Are Used In The Preventive Vaccines Market Segment Analysis?

The preventive vaccines market covered in this report is segmented –

1) By Type: Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines

2) By Disease Type: Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, Other Disease Types

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Other Distribution Channels

Subsegments:

1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine, Varicella (Chickenpox) Vaccine, Oral Polio Vaccine (OPV), Yellow Fever Vaccine, Rotavirus Vaccine, Bacillus Calmette-Guérin (BCG) Vaccine

2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV), Hepatitis A Vaccine, Rabies Vaccine, Influenza (Inactivated) Vaccine, Japanese Encephalitis Vaccine

3) By Toxoid Vaccines: Tetanus Toxoid Vaccine, Diphtheria Toxoid Vaccine, Pertussis (whooping cough) Vaccine

4) By Subunit Vaccines: Hepatitis B Vaccine, Human Papillomavirus (HPV) Vaccine, Pertussis (acellular) Vaccine, Influenza (recombinant protein) Vaccine

5) By Conjugate Vaccines: Pneumococcal Conjugate Vaccine (PCV), Haemophilus influenzae type b (Hib) Vaccine, Meningococcal Conjugate Vaccine

6) By DNA Vaccines: Zika Virus DNA Vaccine, Cytomegalovirus (CMV) DNA Vaccine, Infectious Disease DNA Vaccines

7) By Recombinant Vector Vaccines: Ebola Vaccine (rVSV-ZEBOV), COVID-19 Recombinant Vector Vaccines, Dengue Recombinant Vector Vaccines

Which Trends Are Shaping Growth In The Preventive Vaccines Market?

Leading companies within the preventive vaccines market are prioritizing innovations in vaccine technology, including advanced mRNA technology platforms, to boost vaccine efficacy, enhance safety profiles, accelerate development and manufacturing processes, and offer broader protection against evolving variants of infectious diseases. These advanced mRNA technology platforms represent cutting-edge methodologies that utilize messenger RNA to instruct cells to generate specific proteins, thereby initiating a targeted immune response. For example, in March 2025, Moderna Inc., a US-based biotechnology company, announced FDA approval for mRNA-1283 (mNEXSPIKE), its new COVID-19 vaccine. This vaccine is authorized for adults aged 65 and older and individuals aged 12–64 who have one or more CDC-defined risk factors. The release of mNEXSPIKE signifies a notable leap forward in next-generation mRNA vaccine technology, offering superior stability and simplified storage compared to previous versions. This progress is projected to improve vaccine accessibility and distribution, especially in underserved and remote areas.

Which Firms Are Contributing To The Preventive Vaccines Market Ecosystem?

Major companies operating in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd.

Get The Full Preventive Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Which Region Holds The Highest Market Share In The Preventive Vaccines Market?

North America was the largest region in the preventive vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preventive vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Preventive Vaccines Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Browse Through More Reports Similar to the Global Preventive Vaccines Market 2026, By The Business Research Company

Adult Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/adult-vaccines-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Travel Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/travel-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795